This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.0 (factor VIII deficiency with vascular defect) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Factor VIII deficiency accompanied by vascular defect, von Willebrand disease, vascular hemophilia, Factor VIII deficiency with vascular defect, vWD-type FVIII deficiency, including von Willebrand disease type 2N (Normandy type) |
| C. Adult onset | Likelihood of first presentation in adulthood: very likely — von Willebrand disease, to which this name mainly applies, and especially type 2N (FVIII binding defect type) have a mild to moderate bleeding phenotype and are often first diagnosed in adulthood following surgery, childbirth or tooth extraction; type 2N affects males and females equally (autosomal recessive), so there are cases in which males are misdiagnosed with hemophilia A because of reduced FVIII:C and receive the correct diagnosis in adulthood. |
| 1. History | Historical course from von Willebrand's first description in 1926 to the naming of type 2N (Normandy) in 1991 and the establishment of the current ICD-10 code D68.0 |
| 2. Causes | vWF deficiency or dysfunction due to VWF gene (12p13.3) variants; in particular, loss of FVIII binding capacity due to D'-D3 domain variants (type 2N) |
| 3. Genetics | VWF 12p13.3, 178 kb, 52 exons; D'-D3 domain variants (type 2N, AR); beware of the chromosome 22 pseudogene; influence of blood group O |
| 4. General epidemiology | vWD type 2N is about 1–5% of all vWD; autosomal recessive → males and females affected equally; notable cases reclassified from misdiagnosed hemophilia A |
| 5. Pathophysiology | Loss of the FVIII-protective function of vWF → shortened FVIII half-life → reduced FVIII:C → delayed intrinsic coagulation pathway |
| 6. Symptoms | Mild to moderate bleeding (type 2N); nosebleeds, gum bleeding, heavy menstrual bleeding, excessive bleeding after surgery or tooth extraction; spontaneous joint and muscle bleeding when accompanied by type 3 |
| 7. Signs | Prolonged APTT, reduced FVIII:C, markedly reduced vWF:FVIII binding assay (key finding of type 2N), normal vWF:Ag (type 2N) |
| 8. Screening | When APTT + FVIII:C are reduced, differentiate hemophilia A from vWD type 2N; check for female involvement, family history and whether platelet function is normal |
| 9. Diagnosis | vWF:FVIII binding assay (binding capacity below 30% strongly suggests type 2N) + VWF D'-D3 gene analysis (long-range PCR) |
| 10. Treatment | DDAVP (limited effect in type 2N), vWF concentrate + FVIII concentrate in combination, tranexamic acid, monitoring during pregnancy |
| 11. Prognosis | Normal life expectancy with appropriate treatment; when misdiagnosed as hemophilia A, poor treatment effect due to shortened FVIII half-life |
| 12. Prevention | Genetic counseling (AR inheritance), VWF D'-D3 carrier testing, prenatal diagnosis/PGT, DDAVP challenge test, registration at a hemophilia treatment center |
| 13. References | Mazurier C, et al. Blood. 1990 … and 9 other articles |
In the early 20th century, clinicians began to recognize the existence of an unusual bleeding disorder in which the bleeding time was markedly prolonged despite a normal platelet count and which was transmitted in an autosomal manner to family members, including women. The Finnish physician Erik Adolf von Willebrand, while following a family from the Åland Islands in 1926, described in detail the severe bleeding tendency repeatedly observed in this family and reported it in Finska Läkaresällskapets Handlingar. He presumed that, unlike hemophilia A, the disease affected women equally, that the platelet count was normal but the capillary bleeding time was markedly prolonged, and that there was a fundamental defect in the interaction between the vessel wall and platelets. At the time he named this disease "hereditary pseudohemophilia (hereditär pseudohemofili)".
During this period, researchers gradually recognized that some groups of patients with reduced FVIII activity were clearly distinct from classic hemophilia A (X-linked recessive) in sex distribution, bleeding pattern and abnormalities of vascular components. In particular, the concept that many female patients were included, the bleeding time was prolonged, and a deficiency of some substance related to the vascular endothelium was involved became the historical origin of this name, that is, the expression "Factor VIII deficiency with vascular defect". This name was a conceptual expression that anticipated the dual function of von Willebrand factor (vWF), revealed later—mediating platelet adhesion and stabilizing FVIII in plasma.
In the 1950s, it was found that plasma from vWD patients could temporarily correct the FVIII deficiency of patients with hemophilia A. This was a decisive clue suggesting that vWD patients also have FVIII deficiency, but that the deficiency is a secondary phenomenon due to the absence of a separate vascular protein in the blood (later identified as vWF). The recognition that the FVIII reduction in the two diseases arises from different mechanisms began to emerge.
In 1971, Zimmermann et al. developed an immunoelectrophoresis method that independently quantifies vWF antigen (vWF:Ag). With the introduction of this technique, FVIII coagulant activity (FVIII:C) and vWF:Ag could be measured separately for the first time, and it began to be systematically confirmed that vWF acts as the plasma carrier protein of FVIII. From this period, the concept of "vascular defect" was gradually made concrete as a deficiency of vWF secreted by vascular endothelial cells.
The 1980s were a period in which the structure and function of vWF were rapidly elucidated thanks to advances in molecular biology methodology. In 1986, complete cloning of the VWF gene was achieved and the domain structure of the vWF protein was revealed in detail. In particular, it was established that the N-terminal D'-D3 domain of vWF plays a decisive role in binding to FVIII. The concept was established that when this domain is damaged, even if vWF:Ag levels are normal or mildly reduced, vWF loses its ability to protect FVIII from proteases and FVIII:C can be markedly reduced. In 1989, Nishino et al. described a vWD variant with a specific defect in FVIII binding capacity, leaving a pioneering report in this field.
In 1990, Mazurier et al. described a patient with FVIII deficiency but with normal vWF:Ag levels and multimer pattern, and reported for the first time that, unlike normal vWF, this patient's vWF markedly lacked the ability to bind FVIII. In this patient, the reduction in FVIII:C was clearly confirmed to be due to loss of the protective mechanism of vWF, and this was the discovery of the subtype that embodies, in its purest form, the pathophysiology implied by the name "factor VIII deficiency with vascular defect". Later, in 1991, when Mazurier et al. further described this subtype in families from the Normandy region of France, it was named vWD type 2N (Normandy type) and incorporated into the classification system of the International Society on Thrombosis and Haemostasis (ISTH).
In 2006, the ISTH/SSC established the current international standard classification system dividing vWD into type 1 (partial quantitative deficiency), type 2 (qualitative defect: subtypes 2A/2B/2M/2N) and type 3 (complete deficiency). Currently, in the WHO ICD-10, code D68.0 covers von Willebrand disease as a whole, and "Factor VIII deficiency with vascular defect" is listed as an official synonym of this code. This historical name describes a state in which FVIII:C is secondarily reduced due to deficiency or dysfunction of vWF (a protein derived from vascular endothelial cells), and this pathophysiology is most clearly seen in vWD type 2N. Today this name is used in academic and administrative contexts as a historical synonym of von Willebrand disease, and it is being reexamined as an important concept, particularly in the literature on the differential diagnosis of vWD type 2N and hemophilia A.
The core cause of factor VIII deficiency with vascular defect is deficiency or dysfunction of von Willebrand factor (vWF) due to variants in the VWF gene (chromosome 12p13.3). vWF is a large multimeric glycoprotein produced and secreted by vascular endothelial cells and platelets, and it performs a dual function: mediating adhesion between platelets and damaged vascular endothelium, while protecting FVIII in plasma from attack by proteases. When vWF deficiency or dysfunction occurs, both of these hemostatic mechanisms are impaired and a bleeding tendency appears.
The subtype to which this name most characteristically applies is vWD type 2N. In type 2N, variants in the vWF D'-D3 domain (typically Arg854Gln, Cys788Arg, Thr791Met, etc.) markedly reduce the ability of vWF to bind FVIII. In this case, vWF:Ag levels themselves are normal or only mildly reduced, and the platelet-binding functions of vWF (GPIbα binding, collagen binding) are also maintained normally, but the ability to hold and stabilize FVIII is lost. As a result, plasma FVIII is rapidly degraded by proteases and FVIII:C falls to 1–40%, clinically showing a phenotype similar to mild to moderate hemophilia A. Because type 2N is inherited in an autosomal recessive manner, heterozygotes are asymptomatic or have mild symptoms, and clinical symptoms are expressed in homozygotes or compound heterozygotes.
In vWD type 1 (partial quantitative deficiency), vWF:Ag is mildly to moderately reduced, and accordingly the capacity to stabilize FVIII in plasma is also reduced, so FVIII:C may fall to 30–60%. In vWD type 3 (complete deficiency), vWF:Ag is lost to nearly 0 and FVIII is barely protected, so FVIII:C may be severely reduced to 1–10%. In this case there is a risk of spontaneous bleeding comparable to moderate hemophilia A. Thus the name "factor VIII deficiency with vascular defect" historically encompasses the entire vWD spectrum in which FVIII:C is reduced as a result of vWF deficiency.
The VWF gene is located on chromosome 12p13.3, with a total length of about 178 kb, and consists of 52 exons. The mature vWF precursor consists of 2,813 amino acids and is divided into several functional domains (D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK). Of these, the D'-D3 domain is essential for FVIII binding, the A1 domain is involved in platelet GPIbα binding and ristocetin-mediated aggregation, and the A3 domain is involved in collagen binding.
The causative variants of vWD type 2N are mainly distributed in the D' and D3 domains. The D' domain consists of about 38 amino acids and contains acidic residues essential for binding to FVIII. The D3 domain contains four C2-type domains and forms the FVIII-binding surface. Representative variants include Arg854Gln (most frequently reported), Cys788Arg, Thr791Met and Pro812Leu, and these variants alter the three-dimensional structure of vWF, markedly reducing its FVIII-binding affinity.
Type 2N is inherited in an autosomal recessive manner. When both parents are each heterozygous for a D'-D3 variant, there is a 1/4 probability that a child will express symptoms in homozygous or compound heterozygous form. Even when only one parent is a vWD type 1 carrier and the other parent is heterozygous for type 2N, clinical symptoms can appear in a compound heterozygous child. People with blood group O are known to have vWF:Ag on average 25% lower than other blood groups, so in type 2N patients with blood group O, FVIII:C may measure even lower, and blood group must be considered in interpretation.
Chromosome 22 contains a pseudogene (pseudogene VWF) with sequences similar to exons 51–52 of the VWF gene. This pseudogene can cause false-positive results in general PCR-based genetic analysis or be confused with true VWF variants. Therefore, when analyzing the D'-D3 domain, the pseudogene must be distinguished from the actual VWF gene by long-range PCR or haplotype analysis, and this point must also be specially considered in the design of next-generation sequencing (NGS) panels.
vWD type 2N is a rare subtype that accounts for about 1–5% of all vWD patients, and accurate absolute prevalence statistics have not yet been established. Because diagnosis is difficult and it is often misdiagnosed as hemophilia A, the actual prevalence may be higher than reported figures. The fact that males and females are affected equally due to autosomal recessive inheritance is the key difference from hemophilia A, which is X-linked recessive. For this reason, cases in which male patients are misdiagnosed with hemophilia A based only on reduced FVIII:C and then reclassified as type 2N after reevaluation in adulthood are reported intermittently worldwide.
For von Willebrand disease as a whole, about 1% of the general population is estimated to carry a VWF variant, but the clinical prevalence with bleeding symptoms is estimated at about 100–125 per 1 million people. This is the highest prevalence among hereditary bleeding disorders, and it occurs regardless of sex. vWD type 1 accounts for about 70–80% of the total, type 2 subtypes for 15–25%, and type 3 is the rarest at about 1–3 per 1 million people. The size of the patient group covered by the name "factor VIII deficiency with vascular defect" is the same as all vWD under ICD-10 D68.0.
In Korea, independent registry statistics for vWD type 2N have not yet been established. Cases in which patients being treated for hemophilia A at hemophilia treatment centers are rediagnosed with vWD type 2N through poor treatment response or family history analysis are reported intermittently, and as comprehensive vWF function testing becomes more widely available, it is expected that the actual number of patients can be determined. When registered for rare disease Special Copayment Reduction (V009), the benefit of a 10% copayment for 5 years applies.
Under normal conditions, plasma FVIII circulates in the form of a complex bound to vWF. vWF physically envelops inactive FVIII, blocking premature degradation by proteases—activated protein C (APC), FXa, thrombin, TFPI, etc.—and maintains the plasma half-life of FVIII at about 12–14 hours. This binding is a noncovalent interaction in which the D'-D3 domain of vWF binds to the C2 domain and acidic sequences of FVIII.
When vWF:Ag is reduced, as in vWD type 1 or type 3, the absolute amount of vWF in plasma becomes insufficient and the capacity to protect FVIII decreases. In the absence of the protective protein, FVIII is exposed to proteases and its half-life is shortened to 2–6 hours, with a proportional reduction in plasma FVIII:C. Type 1 shows a mild reduction in FVIII:C, and type 3 a severe reduction (1–10%).
In vWD type 2N, vWF:Ag levels and platelet-binding functions (GPIbα binding, collagen binding, ristocetin-mediated aggregation) are normal or mildly reduced, but FVIII binding capacity is specifically lost due to amino acid variants in the D'-D3 domain. Because the secreted vWF cannot hold FVIII, free FVIII is rapidly degraded and FVIII:C falls to 1–40%. Because platelet adhesion function is preserved, the bleeding time (or PFA-100 closure time) is often normal or borderline. This feature produces the distinctive laboratory findings of type 2N.
As a result of reduced FVIII:C, the efficiency of forming the tenase complex (FVIIIa-FIXa) in the intrinsic coagulation pathway (involving FVIII, FIX, FXI, FXII) decreases, and FX activation and thrombin generation are delayed. As a result, the initial platelet plug formed after vascular injury is not sufficiently reinforced by the fibrin mesh and may dissolve early, causing persistent bleeding. This pathophysiology is more severe the lower the FVIII:C.
FVIII:C in patients with vWD type 2N is usually at 1–40%, a range similar to mild to moderate hemophilia A. Spontaneous joint bleeding and intramuscular hematomas are rare unless FVIII:C is extremely low, and the main symptom is excessive bleeding triggered by trauma, surgery, tooth extraction or childbirth. Nosebleeds (epistaxis), gum bleeding, recurrent skin bruising and mucosal bleeding are commonly observed. In female patients, heavy menstrual bleeding (menorrhagia) often persists from menarche, and in some cases postpartum hemorrhage at delivery in adulthood appears as the first serious bleeding episode.
In vWD type 1, vWF:Ag and FVIII:C are both mildly reduced (FVIII:C at 30–60%), so bleeding is often not prominent in daily life and appears as excessive bleeding only during surgery, tooth extraction or trauma. The typical course is that the disease goes undiagnosed for a long time with mild symptoms such as frequent nosebleeds or easy bruising and is diagnosed in adulthood following a surgical procedure.
In vWD type 3, vWF is almost completely deficient, and FVIII:C falls to 1–10%. This degree of FVIII:C reduction means a bleeding risk comparable to moderate hemophilia A, and spontaneous joint bleeding, muscle hematomas and mucosal bleeding can all occur. When recurrent joint bleeding persists over a long period, joint damage similar to hemophilic arthropathy can result, so FVIII management in type 3 vWD is particularly important.
The laboratory findings in factor VIII deficiency with vascular defect differ somewhat depending on the related vWD subtype, but the key finding is the combination of APTT prolongation and reduced FVIII:C. The platelet count is generally normal.
In male patients found to have both APTT prolongation and reduced FVIII:C, clinicians tend to suspect hemophilia A first. However, when the following clinical clues are present, vWD type 2N should be actively differentiated.
When there is a bleeding tendency or abnormal findings are found on preoperative evaluation, it is recommended to perform the following basic screening tests simultaneously: complete blood count (including platelet count), PT, APTT, FVIII:C (one-stage assay), vWF:Ag, vWF:RCo. Comprehensive analysis of the pattern of results of these three (FVIII:C, vWF:Ag, vWF:RCo) allows preliminary differentiation of most vWD subtypes and hemophilia A. In female relatives with a family history, performing the vWF:FVIII binding assay early increases diagnostic efficiency.
Factor VIII deficiency with vascular defect (especially vWD type 2N) is confirmed through the following stepwise tests.
Step 1 — Basic coagulation tests: The APTT is performed to confirm an intrinsic pathway abnormality, and FVIII:C is measured by the one-stage and chromogenic assays. A discrepancy between the one-stage and chromogenic results (lower on the one-stage assay) may appear in type 2N or some FVIII variants.
Step 2 — vWF quantitative and functional tests: vWF:Ag (immunological quantification), vWF:RCo (GPIbA method or GPIbM recombinant protein method), platelet function analysis (PFA-100/200 closure time) and RIPA are performed. In type 2N, a characteristic pattern appears in which vWF:Ag and vWF:RCo are normal and the PFA-100 is normal, but only FVIII:C is reduced.
Step 3 — vWF:FVIII binding assay (confirmatory test): The ability of the patient's plasma vWF to bind externally added normal FVIII is quantified by ELISA. Binding capacity below 30% strongly suggests vWD type 2N, and this is the key finding for diagnosing type 2N.
Step 4 — VWF gene analysis: Analysis of the entire VWF gene or focused analysis of the D'-D3 domain is performed using next-generation sequencing (NGS). To avoid confusion with the pseudogene, long-range PCR or haplotype-based analysis is essential. Identifying the responsible variant through genetic analysis makes carrier testing within the family and genetic counseling possible.
| Feature | vWD type 2N | Hemophilia A |
|---|---|---|
| Sex distribution | Males and females equally (AR inheritance) | Male predominance (XR inheritance) |
| vWF:Ag | Normal or mildly reduced | Normal |
| vWF:RCo | Normal | Normal |
| FVIII:C | Reduced (1–40%) | Reduced (1–40%) |
| PFA-100 closure time | Normal or borderline | Normal |
| vWF:FVIII binding capacity | Markedly reduced (<30%) | Normal |
| F8 gene variant | None | Present |
| VWF D'-D3 variant | Present | None |
| Sustained DDAVP response | Poor (FVIII:C remains reduced) | Good (sustained FVIII:C rise) |
DDAVP is a drug that releases vWF from Weibel-Palade bodies in endothelial cells, transiently raising plasma vWF:Ag and FVIII:C 2–4-fold. In vWD type 1, vWF:Ag and FVIII:C rise together, so it is used effectively for minor bleeding and minor surgery. However, in vWD type 2N, the vWF released by DDAVP also has the FVIII binding defect, so even if FVIII:C rises transiently at first, the vWF-FVIII complex is not maintained and FVIII:C quickly falls again. Therefore, in type 2N, a test infusion must be performed before DDAVP use to check FVIII:C at 1 hour and 4 hours after treatment, and if a poor response is confirmed, treatment should be switched to vWF concentrate.
Plasma-derived vWF concentrates (e.g., Haemate P, Wilate) supply exogenous vWF with intact FVIII-binding capacity, stabilizing plasma FVIII in patients with type 2N. vWF concentrate alone can induce a rise in FVIII:C by stabilizing endogenous FVIII, but when FVIII:C is severely reduced (especially around surgery), FVIII concentrate is added to achieve a rapid rise in FVIII:C. Recombinant vWF (Vonvendi/Veyvondi) has also been available since 2019 and carries a lower infection risk than plasma-derived products.
Tranexamic acid is an antifibrinolytic that inhibits fibrin degradation and is used together with vWF/FVIII products or alone for mucosal bleeding episodes such as nosebleeds, gum bleeding, bleeding after tooth extraction and heavy menstrual bleeding. Oral contraceptives help control heavy menstrual bleeding in female patients. During pregnancy, vWF and FVIII:C tend to rise physiologically in the third trimester, but this effect is limited in type 2N, so when planning delivery a plan for vWF concentrate use should be made in advance in collaboration between a hematologist and an obstetrician.
During bleeding episodes or around surgery, the goal is to maintain FVIII:C at the target treatment level (minor surgery: 50% or higher; major surgery: 80–100%). Treatment response is monitored by regularly measuring FVIII:C, vWF:Ag and vWF:RCo. In type 2N, it is ideal to confirm with the vWF:FVIII binding assay whether the administered vWF concentrate is adequately stabilizing FVIII.
When vWD type 2N is accurately diagnosed and appropriate treatment—vWF concentrate or combined vWF+FVIII products—is given, life expectancy is normal in most patients. With appropriate management of bleeding episodes, long-term joint damage or other fatal complications do not occur. Regular follow-up by a hematologist and prompt treatment when bleeding episodes occur are the key factors determining prognosis.
When misdiagnosed as hemophilia A and given FVIII concentrate alone, the infused FVIII circulates in the patient's body without vWF to stabilize it, so the half-life of FVIII is markedly shortened (12–14 hours → 2–6 hours). As a result, prophylaxis is poorly effective, bleeding episodes recur, and FVIII:C quickly falls below the lower limit even with appropriate dosing intervals. In such misdiagnosis situations, patients may be continuously exposed to bleeding risk without receiving appropriate treatment. Adding vWF concentrate or switching to it alone normalizes the FVIII half-life and markedly improves the treatment effect.
In female patients with type 2N, vWF and FVIII:C generally rise physiologically in the third trimester, but in type 2N the secreted vWF cannot sufficiently stabilize FVIII, so this rise is limited. Because the risk of delivery and postpartum bleeding is higher than in normal pregnant women, regular monitoring of vWF:Ag, vWF:RCo and FVIII:C during pregnancy is essential, and a plan for vWF concentrate use before delivery should be established.
Because vWD type 2N is inherited in an autosomal recessive manner, it is important to confirm that both of the patient's parents are each heterozygous for a D'-D3 domain variant. Heterozygous carriers are generally asymptomatic or may show a mild vWD type 1-like phenotype. Genetic counseling should accurately convey the risk of disease in children (25% when both parents are heterozygous) and recommend screening of siblings and the extended family.
Carriers are identified by molecular genetic analysis of the VWF gene (D'-D3 domain). Long-range PCR-based analysis is recommended to avoid confusion with the pseudogene. In high-risk couples, prenatal diagnosis by chorionic villus sampling (CVS) or amniocentesis is possible, and preimplantation genetic testing (PGT) linked to in vitro fertilization may also be an option.
After diagnosis, before any surgical procedure (including tooth extraction), a DDAVP challenge test is performed after prior consultation with a hematologist, and if the response is poor, a plan for vWF concentrate use is established. Tranexamic acid can be used adjunctively around surgery to prevent mucosal bleeding.
Patients are educated to avoid drugs that inhibit platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs). In female patients, tranexamic acid or oral contraceptives are considered to control heavy menstrual bleeding. Registering for rare disease Special Copayment Reduction (V009) and registering at a specialized hemophilia/vWD treatment center to establish continuous follow-up and a rapid response system for crisis situations are the key to long-term prevention.